Last reviewed · How we verify
Phenlarmide
Phenlarmide is a Small molecule drug developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. It is currently in Phase 1 development. Also known as: FLZ-150mg, FLZ-300mg, FLZ-600mg, FLZ-900mg.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Phenlarmide |
|---|---|
| Also known as | FLZ-150mg, FLZ-300mg, FLZ-600mg, FLZ-900mg |
| Sponsor | Shijiazhuang Yiling Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets (PHASE1)
- A Clinical Study Trial of Phenlarmide in China (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phenlarmide CI brief — competitive landscape report
- Phenlarmide updates RSS · CI watch RSS
- Shijiazhuang Yiling Pharmaceutical Co. Ltd portfolio CI
Frequently asked questions about Phenlarmide
What is Phenlarmide?
Who makes Phenlarmide?
Is Phenlarmide also known as anything else?
What development phase is Phenlarmide in?
Related
- Manufacturer: Shijiazhuang Yiling Pharmaceutical Co. Ltd — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: FLZ-150mg, FLZ-300mg, FLZ-600mg, FLZ-900mg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing